NCT05718791Recruiting

CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

Henry Ford Health System

Start Date

5/10/2023

Completion Date

12/30/2027

Summary

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

Eligibility Criteria

Age Range: 18 years to 80 years

Inclusion Criteria: * Patients \>18 year old admitted for allo SCT PB for malignant disease.

Interventions

DIAGNOSTIC_TEST

blood sample

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

GVHD,Acute

Locations

Henry Ford Health System

Detroit, Michigan 48202

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.